Literature DB >> 1470308

Benextramine-neuropeptide Y (NPY) binding site interactions: characterization of 3H-NPY binding site heterogeneity in rat brain.

M B Doughty1, K Li, L Hu, S S Chu, R Tessel.   

Abstract

Pre-incubation of rat brain membranes with 200 microM benextramine followed by extensive dilution and washing to remove unbound ligand reduced Bmax for N-[propionyl-3H]-NPY (3H-NPY) specific binding by 61% relative to control membranes treated identically but in the absence of benextramine. When rat brain membranes were co-incubated with 3H-NPY and 57 microM benextramine, there was a significant shift to the right; the apparent Kd for 3H-NPY binding increased two-fold relative to control membranes. These data are consistent with the hypothesis that benextramine is a competitive and irreversible ligand for a population (60-65%) of rat brain NPY binding sites. 'Paired tube' assays were then used to determine the selectivity of these benextramine-sensitive and insensitive 3H-NPY binding site populations. PYY, NPY and NPY13-36 each displaced 100% of 3H-NPY from rat brain membrane binding sites both in the absence and presence of 1 mM benextramine. In contrast, [Leu31,Pro34]NPY displayed the same binding site selectivity as benextramine in displacing 65% of 3H-NPY from specific binding sites on untreated rat brain membranes, and it failed to displace 3H-NPY from membranes treated with 1 mM benextramine. Thus the selectivity of the benextramine-insensitive 3H-NPY binding site population--PYY > = NPY > NPY13-36 >> [Leu31,Pro34]NPY--is characteristic of a Y2-like NPY binding site population, while the benextramine-sensitive 3H-NPY binding sites appear to be a Y1-like binding site population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1470308     DOI: 10.1016/0143-4179(92)90119-h

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  4 in total

1.  Discrimination by benextramine between the NPY-Y1 receptor subtypes present in rabbit isolated vas deferens and saphenous vein.

Authors:  S Palea; M Corsi; J M Rimland; D G Trist
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

2.  Neuropeptide Y depresses GABA-mediated calcium transients in developing suprachiasmatic nucleus neurons: a novel form of calcium long-term depression.

Authors:  K Obrietan; A N van den Pol
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

3.  Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.

Authors:  S Palea; M Corsi; J M Rimland; D G Trist; E Ratti
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

4.  Neuropeptide Y acylation chemistry in aqueous solution: significance to synthesis of a peptide-based photoaffinity label.

Authors:  L Hu; M B Doughty
Journal:  J Protein Chem       Date:  1994-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.